Across 3 studies, 1 reported a small beneficial effect on blood cholesterol (significant reduction in total cholesterol, LDL-C, and triglycerides in migraine patients), while 2 found neutral effects (no significant change). The overall evidence suggests a small and inconsistent effect, with a median study duration of 70 days. Most studies were in clinical populations (MASLD, migraine, MDD), but doses varied (600 mg to 1.8 g EPA/DHA per day).
Caveats: Evidence base is small (only 3 studies) — conclusions should be considered preliminary. Many of the included studies did not reach statistical significance — effect may be smaller than the predominant direction suggests. The only significant benefit was observed in a small trial of migraine patients; the larger meta-analysis found no significant effect. Doses and populations varied, and no form data were reported.
Total Cholesterol [TC, SMD: -0.34 (95% CI: -0.70 to 0.01)]
Blood lipid indexes TC, LDL-C, and TG were reduced
Venous blood samples were collected...to evaluate...cholesterol... (No significant effect reported for this outcome)